Rheumatology Network's Top 5: November 12, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 12, 2021.

Related Videos
Related Content

Janssen Develops Programs to Support Health Equity in Psoriatic Disease

May 25th 2023

Relatable Rheumatology: Making the Invisible Visible Using Patient-Reported Outcomes in Research

May 26th 2023

Apremilast Benefits Psoriatic, Cardiometabolic Outcomes Regardless of Diabetes Status

May 9th 2023

Introducing the Relatable Rheumatology: From Stories to Studies Podcast

May 26th 2023

Study Offers Overview of Features, Outcomes, Treatment for Immune-Mediated Necrotizing Myopathy

May 8th 2023

Over Half of Patients With axSpA, IBD Achieved Clinical Remission After 12 Months of TNF Treatment

May 7th 2023

Janssen Develops Programs to Support Health Equity in Psoriatic Disease

May 25th 2023

Relatable Rheumatology: Making the Invisible Visible Using Patient-Reported Outcomes in Research

May 26th 2023

Apremilast Benefits Psoriatic, Cardiometabolic Outcomes Regardless of Diabetes Status

May 9th 2023

Introducing the Relatable Rheumatology: From Stories to Studies Podcast

May 26th 2023

Study Offers Overview of Features, Outcomes, Treatment for Immune-Mediated Necrotizing Myopathy

May 8th 2023

Over Half of Patients With axSpA, IBD Achieved Clinical Remission After 12 Months of TNF Treatment

May 7th 2023

Janssen Develops Programs to Support Health Equity in Psoriatic Disease

May 25th 2023

Relatable Rheumatology: Making the Invisible Visible Using Patient-Reported Outcomes in Research

May 26th 2023

Apremilast Benefits Psoriatic, Cardiometabolic Outcomes Regardless of Diabetes Status

May 9th 2023

Introducing the Relatable Rheumatology: From Stories to Studies Podcast

May 26th 2023

Study Offers Overview of Features, Outcomes, Treatment for Immune-Mediated Necrotizing Myopathy

May 8th 2023

Over Half of Patients With axSpA, IBD Achieved Clinical Remission After 12 Months of TNF Treatment

May 7th 2023
© 2023 MJH Life Sciences

All rights reserved.